5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-[2'',6''-di-O-(4-fluorobenzoyl)-3'',4''-O-isopropylidene]galactosyl-4H-chromen- | 1262615-41-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-[2'',6''-di-O-(4-fluorobenzoyl)-3'',4''-O-isopropylidene]galactosyl-4H-chromen-
• 英文别名: 5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-[2'',6''-di-O-(4-fluorobenzoyl)-3'',4''-O-isopropylidene]galactosyl-4H-chromen-4-one；[(3aS,4R,6S,7R,7aS)-6-[2-(2,2-diphenyl-1,3-benzodioxol-5-yl)-4-oxo-5,7-bis(phenylmethoxy)chromen-3-yl]oxy-7-(4-fluorobenzoyl)oxy-2,2-dimethyl-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yl]methyl 4-fluorobenzoate
• CAS: 1262615-41-7
• 化学式: C₆₅H₅₀F₂O₁₄
• 分子量: 1093.1
• InChiKey: DFVHPTQKMNVYKJ-IBOKNALQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.7
• 重原子数：
  81
• 可旋转键数：
  18
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  153
• 氢给体数：
  0
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-[2'',6''-di-O-(4-fluorobenzoyl)-3'',4''-O-isopropylidene]galactosyl-4H-chromen- 在 盐酸 作用下， 以 甲醇 为溶剂， 以79%的产率得到5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-[2'',6''-di-O-(4-fluorobenzoyl)]galactosyl-4H-chromen-4-one
  参考文献：
  名称：

  Quercetin Diacylglycoside Analogues Showing Dual Inhibition of DNA Gyrase and Topoisomerase IV as Novel Antibacterial Agents

  摘要：

  A structure-guided molecular design approach was used to optimize quercetin diacylglycoside analogues that inhibit bacterial DNA gyrase and topoisomerase IV and show potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. In this paper, such novel 3,7-diacylquercetin, quercetin 6 ''-acylgalactoside, and quercetin 2 '',6 ''-diacylgalactoside analogues of lead compound 1 were prepared to assess their target specificities and preferences in bacteria. The significant enzymatic inhibition of both Escherichia coli DNA gyrase and Staphylococcus aureus topoIV suggest that these compounds are dual inhibitors. Most of the investigated compounds exhibited pronounced inhibition with MIC values ranging from 0.13 to 128 mu g/mL toward the growth of multidrug-resistant Gram-positive methicillin-resistant S. aureus, methicillin sensitive S. aureus, vancomycin-resistant enterococci (VRE), vancomycin intermediate S. aureus, and Streptococcus pneumoniae bacterial strains. Structure activity relationship studies revealed that the acyl moiety was absolutely essential for activity against Gram-positive organisms. The most active compound 5i was 512-fold more potent than vancomycin and 16-32-fold more potent than 1 against VRE strains. It also has realistic in situ intestinal absorption in rats and showed very low acute toxicity in mice. So far, this compound can be regarded as a leading antibacterial agent.

  DOI：

  10.1021/jm200010x
• 作为产物：
  描述：

  5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-galactosyl-4H-chromen-4-one 在 4-二甲氨基吡啶 、 硫酸 、 copper(II) sulfate 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 5,7-dibenzyloxy-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3-β-D-[2'',6''-di-O-(4-fluorobenzoyl)-3'',4''-O-isopropylidene]galactosyl-4H-chromen-
  参考文献：
  名称：

  Quercetin Diacylglycoside Analogues Showing Dual Inhibition of DNA Gyrase and Topoisomerase IV as Novel Antibacterial Agents

  摘要：

  A structure-guided molecular design approach was used to optimize quercetin diacylglycoside analogues that inhibit bacterial DNA gyrase and topoisomerase IV and show potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. In this paper, such novel 3,7-diacylquercetin, quercetin 6 ''-acylgalactoside, and quercetin 2 '',6 ''-diacylgalactoside analogues of lead compound 1 were prepared to assess their target specificities and preferences in bacteria. The significant enzymatic inhibition of both Escherichia coli DNA gyrase and Staphylococcus aureus topoIV suggest that these compounds are dual inhibitors. Most of the investigated compounds exhibited pronounced inhibition with MIC values ranging from 0.13 to 128 mu g/mL toward the growth of multidrug-resistant Gram-positive methicillin-resistant S. aureus, methicillin sensitive S. aureus, vancomycin-resistant enterococci (VRE), vancomycin intermediate S. aureus, and Streptococcus pneumoniae bacterial strains. Structure activity relationship studies revealed that the acyl moiety was absolutely essential for activity against Gram-positive organisms. The most active compound 5i was 512-fold more potent than vancomycin and 16-32-fold more potent than 1 against VRE strains. It also has realistic in situ intestinal absorption in rats and showed very low acute toxicity in mice. So far, this compound can be regarded as a leading antibacterial agent.

  DOI：

  10.1021/jm200010x

文献信息

• Quercetin Diacylglycoside Analogues Showing Dual Inhibition of DNA Gyrase and Topoisomerase IV as Novel Antibacterial Agents
  作者：Abugafar M. L. Hossion、Yoshito Zamami、Rafiya K. Kandahary、Tomofusa Tsuchiya、Wakano Ogawa、Akimasa Iwado、Kenji Sasaki

  DOI：10.1021/jm200010x

  日期：2011.6.9

  A structure-guided molecular design approach was used to optimize quercetin diacylglycoside analogues that inhibit bacterial DNA gyrase and topoisomerase IV and show potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. In this paper, such novel 3,7-diacylquercetin, quercetin 6 ''-acylgalactoside, and quercetin 2 '',6 ''-diacylgalactoside analogues of lead compound 1 were prepared to assess their target specificities and preferences in bacteria. The significant enzymatic inhibition of both Escherichia coli DNA gyrase and Staphylococcus aureus topoIV suggest that these compounds are dual inhibitors. Most of the investigated compounds exhibited pronounced inhibition with MIC values ranging from 0.13 to 128 mu g/mL toward the growth of multidrug-resistant Gram-positive methicillin-resistant S. aureus, methicillin sensitive S. aureus, vancomycin-resistant enterococci (VRE), vancomycin intermediate S. aureus, and Streptococcus pneumoniae bacterial strains. Structure activity relationship studies revealed that the acyl moiety was absolutely essential for activity against Gram-positive organisms. The most active compound 5i was 512-fold more potent than vancomycin and 16-32-fold more potent than 1 against VRE strains. It also has realistic in situ intestinal absorption in rats and showed very low acute toxicity in mice. So far, this compound can be regarded as a leading antibacterial agent.